Fusion Antibodies Plc, the antibody discovery and engineering specialist, announced a contract worth more than £85,000 with a US-based specialty division of a global pharmaceutical company on 22 October 2026. The award came a week after an AGM statement on 15 October in which the company disclosed a sharp fall in first-half Revenue and said it was reviewing its Working Capital requirements, with cash reserves of about £135,000.

What the company does

Fusion Antibodies provides contract research services to pharmaceutical and biotechnology companies, including antibody discovery, cell line development, transient gene expression and structural studies such as cryogenic electron microscopy. It also runs grant-funded research with Queen's University Belfast. It has also developed OptiMAL, a proprietary antibody discovery platform that it launched commercially in December 2025. The company is led by chief executive Dr Adrian Kinkaid.

Latest developments

The October contract covers transient gene expression and a cryogenic electron microscopy study. The company described the work as repeat Business and technologically complex, supporting its aim of working with larger pharmaceutical clients. It expects to complete the project within the current financial year.

The AGM statement painted a more difficult trading picture. Revenue for the first half of the 2027 financial year fell to £457,000 from £838,000 a year earlier, according to a summary of the unaudited figures, and gross Margin dropped to 10% from 30%. The company has introduced a recruitment freeze. On the research side, it reported promising in-vivo results for its DR5 therapeutic antibody programme in colorectal cancer studies and said negotiations were continuing over further use of OptiMAL by the US National Cancer Institute.

Fusion has also been building its Patent estate, with a Canadian patent for OptiMAL announced on 9 September 2026, acceptance of an Australian patent in August, and grants in Japan alongside existing US patents. A new customer-focused website was launched on 5 October.

Financial and Dividend picture

Final results published on 14 September 2026 covered the year to 31 March 2026. Revenue rose to about £2.1m from £1.97m, helped by an intellectual property transfer to Finn Therapeutics worth £250,000, with payment expected in the 2027 financial year after a Finn fundraise. Gross margin was reported at 53%, up from 22%. The operating loss narrowed to £1.13m, and other Operating Income of £872,000 came mainly from a grant programme. Year-end cash was £1.04m. A grant-funded DR5 project with the university could bring in up to £545,000. No dividend was reported.

Sector and index context

Fusion is one of the smaller life sciences companies in the FTSE AIM All Share Index. Its shares were trading at 12.5p in May 2026, down nearly 11% on the day the unaudited full-year figures were released. Small contract research organisations have faced uneven Demand as biotech funding conditions have fluctuated, making revenue from individual projects lumpy.

Key risks

The most pressing risk is liquidity. With cash of around £135,000 reported in October and a review of working capital under way, the company may need fresh funding, which could dilute shareholders. Revenue depends on a small number of contracts, and margins can swing sharply with project mix. Commercial uptake of OptiMAL and the outcome of the NCI negotiations remain uncertain.

What to watch next

Investors will look for the outcome of the working capital review, any fundraising, the half-year report for the six months to 30 September 2026, further contract wins and progress on OptiMAL licensing and the DR5 programme.